Efficacy Study of Sintilimab Combined with Albumin-Bound Paclitaxel in Second-line Treatment of Advanced Gastric Cancer
Objective To explore the value of combining sintilimab and albumin-bound paclitaxel in the second-line treatment of patients with advanced gastric cancer.Methods A total of 62 patients with advanced gastric cancer who were admitted to Luoyang Petrochemical Hospital between December 2021 and June 2023 were selected.Based on different chemotherapy regimens,patients were divided into a study group(n=31)receiving sintilimab combined with albumin-bound paclitaxel and a control group(n=31)receiving only albumin-bound paclitaxel.The two groups were compared for objective response rate,immune function indicators,liver and kidney function indicators,quality of life,and adverse reactions.Results The objective response rate in the study group(45.16%)was significantly higher than that in the control group(19.35%)(P＜0.05).Before treatment,there were no significant differences in immune indicators between the two groups(P＞0.05).After treatment,the immune indicators decreased in both groups,with the study group showing significantly higher levels than the control group(P＜0.05).There were no significant differences in gastric cancer scale scores before treatment(P＞0.05),but after treatment,the scores improved in both groups,with the study group scoring significantly higher than the control group(P＜0.05).No significant differences were found between the two groups in liver and kidney function indicators or the occurrence of adverse reactions after treatment(P＞0.05).Conclusion The combination of sintilimab and albumin-bound paclitaxel in second-line treatment for advanced gastric cancer demonstrates favorable clinical efficacy,improves immune function levels,enhances quality of life,and does not increase the risk of liver and kidney damage or other adverse reactions,indicating its clinical application value.
Sintilimabalbumin-bound paclitaxelchemotherapysecond-line treatmentgastric cancer
国家科技期刊平台
NSTL
万方数据
